FOR IMMEDIATE RELEASE | April 20, 2020

Diagnostic biosensor quickly detects SARS-CoV-2 from nasopharyngeal swabs


ACS Nano

According to many experts, early diagnosis and management are critical for slowing the spread of SARS-CoV-2, the new coronavirus that causes COVID-19. Therefore, the race is on to develop diagnostic tests for the virus that are faster, easier and more accurate than existing ones. Now, researchers reporting in ACS Nano have developed a field-effect transistor-based biosensor that detects SARS-CoV-2 in nasopharyngeal swabs from patients with COVID-19, in less than one minute.

Currently, most diagnostic tests for COVID-19 rely on a technique called real-time reverse transcription-polymerase chain reaction (RT-PCR), which amplifies SARS-CoV-2 RNA from patient swabs so that tiny amounts of the virus can be detected. However, the method takes at least 3 hours, including a step to prepare the viral RNA for analysis. Edmond Changkyun Park, Seung Il Kim and colleagues wanted to develop a faster diagnostic test that could analyze patient samples directly from a tube of buffer containing the swabs, without any sample preparation steps.

The team based their test on a field-effect transistor –� a sheet of graphene with high electronic conductivity. The researchers attached antibodies against the SARS-CoV-2 spike protein to the graphene. When they added either purified spike protein or cultured SARS-CoV-2 virus to the sensor, binding to the antibody caused a change in the electrical current. Next, the team tested the technique on nasopharyngeal swabs collected from patients with COVID-19 or healthy controls. Without any sample preparation, the sensor could discriminate between samples from sick and healthy patients. The new test was about 2�4 times less sensitive than RT-PCR, but different materials could be explored to improve the signal-to-noise ratio, the researchers say.

The authors acknowledge funding from the National Research Council of Science and Technology funded by the , Korea and the Korea Health Technology R&D Project through the funded by the , Korea.

The American Chemical Öйú365betÖÐÎĹÙÍø (ACS) is a nonprofit organization chartered by the U.S. Congress. ACSâ€� mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Öйú365betÖÐÎĹÙÍø is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACSâ€� main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive press releases from the American Chemical Öйú365betÖÐÎĹÙÍø, contact [email protected].

###

Follow us:      

Correction

Correction

**A to the journal article was published on Aug. 28, 2020**

Media Contact

ACS Newsroom
newsroom@acs.org

Illustration of SARS-CoV-2 binding to antibodies
An artist’s rendering above shows a new test that quickly detects SARS-CoV-2 (spheres) through binding to antibodies (Y-shapes) on a field-effect transistor.
Adapted from ACS Nano 2020, DOI: 10.1021/acsnano.0c02823
View Larger Image